# Evaluation the Pharmacokinetics, Safety, Tolerability of TK001 in Patients With Neovascular Age-related Macular Degeneration

> **NCT02613559** · PHASE1 · UNKNOWN · sponsor: **Jiangsu T-Mab Biopharma Co.,Ltd** · enrollment: 27 (estimated)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **BIOLOGICAL:** TK001

## Key facts

- **NCT ID:** NCT02613559
- **Lead sponsor:** Jiangsu T-Mab Biopharma Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-11
- **Primary completion:** 2018-06
- **Final completion:** 2018-09
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2018-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02613559

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02613559, "Evaluation the Pharmacokinetics, Safety, Tolerability of TK001 in Patients With Neovascular Age-related Macular Degeneration". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02613559. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*